TMPRSS2-ERG 赋予抗雄激素的抗性:机制和治疗影响
bioRxiv : the preprint server for biology
|June 26, 2025
概括
前列腺癌 (PCa) 中的TMPRSS2-ERG基因融合驱动对ARSI的耐药性. 与AR信号抑制剂一起抑制葡萄糖皮质体受体 (GR) 可能有利于tERG阳性PCa患者.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 前列腺癌 (PCa) 经常涉及TMPRSS2-ERG基因融合.
- 缺乏针对产生的tERG融合蛋白的向疗法.
研究的目的:
- 调查tERG在抗抗雄激素受体信号抑制剂 (ARSI) 的作用.
- 探索针对tERG阳性PCa的治疗策略.
主要方法:
- 来自ARSIs临床试验的活检样本的分析.
- 测试以确定tERG和葡萄糖皮质体受体 (GR) 之间的相互作用.
- 在PCa模型和异种移植中评估GR抑制和皮质醇降低.
主要成果:
- tERG促进对ARSI的耐药性,与GR水平升高相关.
- GR与tERG直接相互作用,增强其稳定性和功能.
- 在tERG阳性模型中抑制GR或皮质醇抑制瘤生长.
- 结合GR和AR抑制显示在聚变阳性异种移植中效果更强.
结论:
- 在前列腺癌中,TMPRSS2-ERG是ARSI抗性的潜在生物标志物.
- 同时抑制GR和AR可能是针对tERG阳性PCa的向治疗.
- 在tERG阳性患者中,皮质类固醇治疗可能是禁忌的.
更多相关视频
06:44Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
13.5K
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
10.7K
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Mitogens and the Cell Cycle
7.0K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
